Member Info for Moneymunch

Motif have now got enough £850k cash in the bank to ensure a successful RTO, they are in discussions with several Healthcare Bio targets and have appointed the high profile and highly respected Chris Wardhaugh to the BoD, who definitley wouldn't have joined the board unless he was confident of a successful conclusion, and no doubt whoever the RTO target is , Lamellar could be highly likely, they will motivated by ilcaprim's phase 11/111 status and the time and money that will be saved given that it can be taken straight into patient trials, and very likely COvid-19 patient trials...the UPside and market cap of the RTO could be considerable from this current bargain low. Gla ;-)

Christopher (Chris) Wardhaugh

Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.

Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.

Commenting, Bruce Williams, Chairman of Motif Bio, said: "We welcome Chris to the Board as we focus on sourcing an appropriate reverse takeover candidate for Motif Bio. We believe that the Company will benefit from Chris's breadth of knowledge and transactional experience and we will provide shareholders with further updates in due course."

Transformational UPside potential from sub 1p...Gla :-)

20p would equate to a market cap of c£100m from MTFS current market cap, and so what value would be attributed to a leading Healthcare Bio with cutting edge technology in combination with iclaprim in Covid-19 patient trials , let alone the value of the company if those patient trials reported positive results.....Transformational potential UPside ahead!!! Gl ;-)

The risk reward is firmly in our favour...RTO news could drop at anytime, and the appointment of Lamellar's highly respected Director to Motifs BoD , speaks volumes. Gla :-)

5th May

Bakground to the Placing

Motif Bio is undertaking the Placing at this time in response to investor demand. In addition, the Placing will strengthen Motif Bio's balance sheet as the Company's Directors continue to focus on sourcing an appropriate reverse takeover candidate for Motif Bio. The Company's Directors are currently in discussions with several companies in the healthcare sector that have expressed an interest in proceeding with a reverse takeover.

The net proceeds of the Placing will be used as follows:

-- To strengthen the Company's balance sheet as the Company's Directors continue the search for an appropriate reverse takeover candidate; and

-- To provide the Company with additional working capital.

Following the Placing, Motif Bio will have cash of approximately GBP815,000 which will provide the Company with sufficient working capital until February 2021. The Directors will continue to impose disciplined cost controls.

Don't be ridiculous bobby, if Lamellar is in the frame, then Chris Wardhaugh and co will be well rewarded on RTO completion. Gl ;-)

No of course I'm not certain, I said fingers crossed , although RTO news could drop at anytime and I'm sure Lamellar's Director who joined Motifs BoD will be using all his influence to get a deal done....exciting times for those invested. Gl :')

3 x 3.45m buys suggests it more likely to rise imho, and or hopefully share suspension tomorrow on RTO confirmation. Gla :'l

Fingers crossed for disclosure of RTO target and share suspension tomorrow. Gla :-)

Lock in, Lock out time fast approaching.....Transformational RTO news could drop at anytime. Gla ;-)

Last chance for sub 1p.....!!!??? Gla ;-)

The  risk reward is firmly in our favour...RTO news could drop at anytime, and the appointment of Lamellar's highly respected Director to Motifs BoD , speaks volumes. Gla :-)

5th May

Bakground to the Placing

Motif Bio is undertaking the Placing at this time in response to investor demand. In addition, the Placing will strengthen Motif Bio's balance sheet as the Company's Directors continue to focus on sourcing an appropriate reverse takeover candidate for Motif Bio. The Company's Directors are currently in discussions with several companies in the healthcare sector that have expressed an interest in proceeding with a reverse takeover.

The net proceeds of the Placing will be used as follows:

-- To strengthen the Company's balance sheet as the Company's Directors continue the search for an appropriate reverse takeover candidate; and

-- To provide the Company with additional working capital. 

Following the Placing, Motif Bio will have cash of approximately GBP815,000 which will provide the Company with sufficient working capital until February 2021. The Directors will continue to impose disciplined cost controls.

5th May

Bakground to the Placing

Motif Bio is undertaking the Placing at this time in response to investor demand. In addition, the Placing will strengthen Motif Bio's balance sheet as the Company's Directors continue to focus on sourcing an appropriate reverse takeover candidate for Motif Bio. The Company's Directors are currently in discussions with several companies in the healthcare sector that have expressed an interest in proceeding with a reverse takeover.

Bobby why do keep posting details of the old Rns and not the latest regarding cash position??? :-)

th May RNS

The net proceeds of the Placing will be used as follows:

-- To strengthen the Company's balance sheet as the Company's Directors continue the search for an appropriate reverse takeover candidate; and

-- To provide the Company with additional working capital. 

Following the Placing, Motif Bio will have cash of approximately GBP815,000 which will provide the Company with sufficient working capital until February 2021. The Directors will continue to impose disciplined cost controls.

Transformational UPside potential from sub 1p...Gla :-)

20p would equate to a market cap of c£100m from MTFS current market cap, and so what value would be attributed to a leading Healthcare Bio with cutting edge technology in combination with iclaprim in Covid-19 patient trials , let alone the value of the company if those patient trials reported positive results.....Transformational potential UPside ahead!!! Gl ;-)

Motif have £850k cash in the bank to ensure a successful RTO , they are in discussions with several Healthcare Bio targets and have appointed the high profile and highly respected Chris Wardhaugh to the BoD, who definitley wouldn't have joined the board unless he was confident of a successful conclusion, and no doubt whoever the RTO target is , Lamellar could be highly likely, they will be motivated by ilcaprim's phase 11/111 status and the time and money that will be saved given that it can be taken straight into patient trials, and very likely Covid-19 patient trials...the UPside and market cap of the RTO target could be considerable from this current bargain low. .....RTO news could drop at anytime.....Gla ;-)

8/4/20

Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOMEâ„¢ Technology

....................

A LAMELLASOMEâ„¢ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.

The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.

Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in‑vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.

Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOMEâ„¢ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."

Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOMEâ„¢ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."

hTtps://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using

There's a very high chance that iclaprim is in formulation with Lamellars technology following the signed agreement to evaluate iclaprim, and especially now that one of Lamellar's Directors has only just joined Motif's BoD at the most crucial time in proceedings. Gla ;-)

1/5/19

Motif Bio Signs Agreement with Lamellar Biomedical

Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections

Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology.

Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.

The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.

Dr. Graham Lumsden, Chief Executive Officer of Motif Bio, said: "We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim."

Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME(TM) technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."

"Hercules will benefit from the future success of Motif Bio and potential upside in a successful monetization of iclaprim."

5th May RNS

The net proceeds of the Placing will be used as follows:

-- To strengthen the Company's balance sheet as the Company's Directors continue the search for an appropriate reverse takeover candidate; and

-- To provide the Company with additional working capital.

Following the Placing, Motif Bio will have cash of approximately GBP815,000 which will provide the Company with sufficient working capital until February 2021. The Directors will continue to impose disciplined cost controls.

RTO news could drop at anytime!!! Gla ;-)

" The Company's Directors are currently in discussions with several companies in the healthcare sector that have expressed an interest in proceeding with a reverse takeover"

Lol, and that's 2 posts from you, you can't keep away.:-)

Ps if you have a few who are determined to undermine deter and discourage a share where you might have a sizeable investment, then it certainly would be lacking if you failed to allow their jaundiced rhetoric to go unchallenged. Gl :'l